The Effect and Safety of <italic style="font-style: italic">Zizao Yangrong Granules</italic> （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with <italic style="font-style: italic">Yin</italic> Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study

Chongxiang XUE; Jia LI; Xu ZHANG; Jingyi ZHANG; Xingyu LU; Huijing DONG; Yixuan YU; Kexin TAN; Yumin ZHENG; Huijuan CUI

doi:10.13288/j.11-2166/r.2022.08.012

您当前的位置：

首页 >

文章列表页 >

The Effect and Safety of Zizao Yangrong Granules （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with Yin Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study

更新时间：2022-04-11

- The Effect and Safety of Zizao Yangrong Granules （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with Yin Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study
- Journal of Traditional Chinese Medicine Vol. 63, Issue 8, Pages: 760-765(2022)
- 作者机构：
  
  1.北京中医药大学，北京市朝阳区北三环东路11号，100029
  2.北京市和平里医院
  3.中日友好医院/国家呼吸中心
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2022.08.012
  CLC：
- Received：18 July 2021，
  
  Revised：2022-01-27，
  
  Published：17 April 2022
- 稿件说明：
移动端阅览
薛崇祥,李嘉,张旭等.滋燥养荣颗粒治疗非小细胞肺癌EGFRIs相关皮肤干燥症阴虚血燥证有效性及安全性的长期随访研究[J].中医杂志,2022,63(08):760-765.

XUE Chongxiang,LI Jia,ZHANG Xu,et al.The Effect and Safety of Zizao Yangrong Granules （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with Yin Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study[J].Journal of Traditional Chinese Medicine,2022,63(08):760-765.
薛崇祥,李嘉,张旭等.滋燥养荣颗粒治疗非小细胞肺癌EGFRIs相关皮肤干燥症阴虚血燥证有效性及安全性的长期随访研究[J].中医杂志,2022,63(08):760-765. DOI： 10.13288/j.11-2166/r.2022.08.012.

XUE Chongxiang,LI Jia,ZHANG Xu,et al.The Effect and Safety of Zizao Yangrong Granules （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with Yin Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study[J].Journal of Traditional Chinese Medicine,2022,63(08):760-765. DOI： 10.13288/j.11-2166/r.2022.08.012.

摘要

目的

评估滋燥养荣颗粒对应用表皮生长因子受体抑制剂（EGFRIs）治疗的非小细胞肺癌患者出现相关皮肤干燥症的长期疗效及安全性。

方法

基于前期临床试验研究对象，即非小细胞肺癌EGFRIs相关皮肤干燥症阴虚血燥证患者66例，其中治疗组与对照组各33例。对照组患者予维生素E乳外用联合安慰剂口服，治疗组患者给予维生素E乳外用联合滋燥养荣颗粒口服，两组均每日1剂，疗程为4周以上。本研究每3个月对患者进行电话随访，记录两组患者无进展生存期（PFS）。对治疗组口服滋燥养荣颗粒8周以上的患者进行问卷随访调查，分析长期服用滋燥养荣颗粒的症状疗效及安全性，采用皮肤生活质量量表（DLQI）评价生活质量。

结果

成功随访54例患者，其中试验组30例，对照组24例。试验组患者中位PFS为41.6（0.60，1.75）个月，对照组为40.9（0.57，1.67）个月，两组差异无统计学意义（HR=0.85，95%

CI：

0.48~1.51，

=0.586）。治疗组共有19例患者服用滋燥养荣颗粒超过8周，至随访截点19例患者中皮肤干燥总有效率84.2%（16/19），全身干燥总有效率89.5%（17/19），瘙痒总有效率72.2%（13/18）。随访截点时19例患者生活质量量表（DLQI）评分中位数为6（5，8）分，相较于用药前中位数4（2，5）分明显升高（

＜0.01）。19例患者中发生不良反应11例，分析原因其中6例与滋燥养荣颗粒治疗无关，无3级以上治疗相关不良事件发生。

结论

非小细胞肺癌EGFRIs相关皮肤干燥症阴虚血燥证患者使用滋燥养荣颗粒不会影响其PFS，长期口服可缓解EGFRIs所致皮肤干燥、瘙痒症状，提高患者生活质量，且安全性良好。

Abstract

Objective

To explore the long-term effect and safety of

Zizao Yangrong Granules

（ZYG，滋燥养荣颗粒） for skin xerosis in non-small cell lung cancer patients with previous treatment of epidermal growth factor receptor inhibitors （EGFRIs）.

Methods

Sixty-six non-small cell lung cancer patients patients with EGFRIs-related skin xerosis in a previous trial were retrospectively included， with 33 patients each in the treatment and control group. Besides the external use of vitamin E emulsion， patients in the treatment group received oral ZYG， while those in the control group were given placebo of ZYG， one dose daily for at least four weeks. The patients were followed up by telephone every 3 months， and the progression-free survival （PFS） of the two groups were recorded. A follow-up questionnaire was conducted among patients who took ZYG for more than 8 weeks， and the clinical effect and safety of long-term ZYG were evaluated. The dermatology life quality index （DLQI） was used to assess the quality of life.

Results

Fifty-four patients were successfully followed， with 30 cases in the treatment group and 24 cases in the control group. Median PFS in the treatment group was 41.6 （0.60， 1.75） months， and that in control group was 40.9 （0.57， 1.67） months， with no statistical difference between groups （HR = 0.85， 95%

0.48 to 1.51，

= 0.586）. A total of 19 patients took ZYG for more than 8 weeks in the treatment group. The overall effective rate was 84.2% （16/19） in relieving skin xerosis， 89.5% （17/19） in relieving body xerosis， and 72.2% （13/18） in relieving pruritus， respectively. Besides， the median DLQI score of the 19 patients was 6 （5， 8）， significantly higher than 4 （2， 5） before treatment （

＜0.001）. Among the 19 patients， there were 11 cases of adverse reactions， and 6 cases were not related to the treatment of ZYG. And there were no treatment-related adverse events of grade 3 or above.

Conclusions

ZYG could not affect PFS of non-small cell lung cancer patients with EGFRIs-related skin xerosis of

yin

deficiency and blood dryness pattern， but long-term oral administration can relieve the dry skin and itching symptoms induced by EGFRIs and improve the quality of life， and is of good safety.

关键词

Keywords

references

SCHILLER JH ， HARRINGTON D ， BELANI CP ， et al . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer ［J］. N Engl J Med ， 2002 ， 346 （ 2 ）： 92 - 98 .

WU YL ， CHENG Y ， ZHOU X ， et al . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer（ARCHER 1050）： a randomised，open-label，phase 3 trial ［J］. Lancet Oncol ， 2017 ， 18 （ 11 ）： 1454 - 1466 .

SORIA JC ， OHE Y ， VANSTEENKISTE J ， et al . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer ［J］. N Engl J Med ， 2018 ， 378 （ 2 ）： 113 - 125 .

PENG Y ， LI Q ， ZHANG J ， et al . Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors ［J］. Biosci Trends ， 2019 ， 12 （ 6 ）： 537 - 552 .

鲁星妤，刘喆，张予辉，等 . 基于真实世界数据的EGFRIs治疗相关皮肤干燥不良反应的流行病学调查［J］. 现代肿瘤医学， 2021 ， 29 （ 20 ）： 3644 - 3648 .

VYUMVUHORE R ， MICHAEL-JUBELI R ， VERZEAUX L ， et al . Lipid organization in xerosis： the key of the problem？［J］. Int J Cosmet Sci ， 2018 ， 40 （ 6 ）： 549 - 554 .

CHMIELINSKA JJ ， KRAMER JH ， MAK IT ， et al . Substance P receptor blocker，aprepitant，inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI，erlotinib ［J］. Mol Cell Biochem ， 2020 ， 465 （ 1/2 ）： 175 - 185 .

徐央波 . 四种外用药物治疗EGFRIs皮肤干燥的自身对照临床研究［D］. 北京：北京中医药大学， 2015 .

张琴，解英 . 解英教授治疗靶向相关性皮疹验案［J］. 中医临床研究， 2016 ， 8 （ 33 ）： 1 - 2 .

PENG YM ， DUAN H ， ZHANG J ， et al . Application of Zizao Yangrong Granules for treating targeted drugs-related skin xerosis： a randomized double-blinded controlled study ［J］. Integr Cancer Ther ， 2020 ， 19 ： 153473542 0924832 . doi： 10.1177/1534735420924832 http://dx.doi.org/10.1177/1534735420924832 .

赫捷，李进，马军，等 . 中国临床肿瘤学会（CSCO）常见恶性肿瘤诊疗指南［M］. 北京：人民卫生出版社， 2020 ： 91 - 132 .

US Department of Health and Human Services ， National Institutes of Health ， National Cancer Institute . Common Terminology Criteria for Adverse Events（CTCAE） Version 5 ［EB/OL］.（ 2017-11-27 ）［ 2020-02-28 ］. https：//evs.nci.nih.gov/ftp1/CTCAE/About.html https://evs.nci.nih.gov/ftp1/CTCAE/About.html .

DETTERBECK FC ， BOFFA DJ ， KIM AW ， et al . The eighth edition lung cancer stage classification ［J］. Chest ， 2017 ， 151 （ 1 ）： 193 - 203 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 ： 216 - 220 .

EISENHAUER EA ， THERASSE P ， BOGAERTS J ， et al . New response evaluation criteria in solid tumours： revised RECIST guideline（version 1.1）［J］. Eur J Cancer ， 2009 ， 45 （ 2 ）： 228 - 247 .

LACOUTURE ME ， MAITLAND ML ， SEGAERT S ， et al . A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group ［J］. Support Care Cancer ， 2010 ， 18 （ 4 ）： 509 - 522 .

郭放 . EGFR-TKI相关皮肤毒性反应的研究现状及最新进展［C］//中国抗癌协会. 第八届全国癌症康复与姑息医学大会论文集 . 青岛：中国抗癌协会， 2012 ： 168 - 173 .

LYNCH TJ JR ， KIM ES ， EABY B ， et al . Epidermal growth factor receptor inhibitor-associated cutaneous to-xicities： an evolving paradigm in clinical management ［J］. Oncologist ， 2007 ， 12 （ 5 ）： 610 - 621 .

FINLAY AY ， KHAN GK . Dermatology Life Quality Index（DLQI）：a simple practical measure for routine clinical use ［J］. Clin Exp Dermatol ， 1994 ， 19 （ 3 ）： 210 - 216 .

KIM JM ， JI JH ， KIM YS ， et al . rhEGF treatment improves EGFR inhibitor-induced skin barrier and immune defects ［J］. Cancers（Basel）， 2020 ， 12 （ 11 ）： 3120 .

URATA Y ， KATAKAMI N ， MORITA S ， et al . Randomized phase Ⅲ study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma： WJOG 5108L ［J］. J Clin Oncol ， 2016 ， 34 （ 27 ）： 3248 - 3257 .

WU YL ， ZHOU C ， HU CP ， et al . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbou-ring EGFR mutations（LUX-Lung 6）： an open-label，randomised phase 3 trial ［J］. Lancet Oncol ， 2014 ， 15 （ 2 ）： 213 - 222 .

GISONDI P ， GEAT D ， MATTIUCCI A ， et al . Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small-cell lung cancer ［J］. Dermatology ， 2021 ， 237 （ 6 ）： 929 - 933 .

刘戴维，崔慧娟，李占林，等 . 中医辨病、辨证、辨症治疗表皮生长因子受体抑制剂相关皮疹的回顾与思考［J］. 环球中医药， 2021 ， 14 （ 7 ）： 1358 - 1362 .

张心悦，彭艳梅，徐央波，等 . 肺腺癌患者应用表皮生长因子受体抑制剂治疗后皮肤不良反应的中医证候特点［J］. 中医杂志， 2015 ， 56 （ 16 ）： 1401 - 1405 .

HUANG XG ， ZHU LH ， ZHOU L ， et al . Multidisciplinary and comprehensive Chinese medicine for advanced non-small cell lung cancer patients： a retrospective study of 855 cases ［J］. Chin J Integr Med ， 2021 ， 27 （ 7 ）： 490 - 495 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Heat-sensitive Moxibustion on Quality of Life and Immune Function in Non-Small Cell Lung Cancer Patients with Qi Deficiency and Phlegm Stasis Syndrome Undergoing Chemotherapy：A Randomized Controlled Trial

The Influence of the Peripheral Immune Score on the Prognosis of Non-small Cell Lung Cancer Treated by Traditional Chinese Medicine and the Construction of the Related Prediction Model

Comprehensive Traditional Chinese Medicine Therapeutic Scheme in Maintenance Treatment for Advanced Non-small Cell Lung Cancer: a Multicenter, Large-sample and Prospective Cohort Study

Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction （升陷汤）

Clinical Observation on 40 Cases of Ascites with Spleen and Kidney Yang Deficiency Syndrome Treated by External Application of Xiaozhang Lishui Powder（消胀利水散） and Moxibustion

Related Author

ZHAN Wenhao

DING Qian

DONG Zhiwei

LI Ting

FU Shumei

TIAN Ning

Tianle LUO

Yiyang ZHOU

Related Institution

Guangdong Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Guangzhou University of Chinese Medicine

Jinan Vocational College of Nurisng，Shandong Pronvince

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Shanghai University of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

The Effect and Safety of Zizao Yangrong Granules （滋燥养荣颗粒） for EGFRIs-related Skin Xerosis with Yin Deficiency and Blood Dryness Pattern： A Long-term Follow-up Study

DOI：10.13288/j.11-2166/r.2022.08.012

摘要

Abstract

关键词

Keywords

references